Pharma BD Deal Intelligence

Sanofi-Aventis Group / ImmunoGen, Inc.

2005 · Co-Development · $18M · Complete

Announcement Sentiment
70
Positive

Sanofi-Aventis extends antibody-drug conjugate (ADC/TAP) research collaboration with ImmunoGen; extension begins Sept 2006 with additional committed funding. Strategically notable ADC platform deal.

Key facts

See the full interactive analysis, sources & comparables →